A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects
Latest Information Update: 02 Feb 2021
At a glance
- Drugs Lemborexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Eisai Inc
- 01 Jan 2021 Results assessing potential of lemborexant for residual morning and next-day effects, including somnolence from 9 studies (E2006-A001-001 Part B, E2006-A001-002, E2006-A001-003, E2006-E044-106, E2006-A001-107, E2006-A001-108, E2006-G000-201, E2006-G000-303 & E2006-G000-304) published in the Postgraduate Medicine.
- 04 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 23 Jan 2014 New trial record